SCHEMBL6079784

SCHEMBL6079784

O=C(O)c1cc(O)c2cc(-c3cccc(Cl)c3)cc(O)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.46
ALOX5 P09917 1/20 0.45
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
GPR35 Q9HC97 1/20 0.41
TET3 O43151 1/20 0.41
BBOX1 O75936 1/20 0.41
VEGFA P15692 1/20 0.41
FLT1 P17948 1/20 0.41
ASPH Q12797 1/20 0.41
TET2 Q6N021 1/20 0.41
KDM8 Q8N371 1/20 0.41
OGFOD1 Q8N543 1/20 0.41
TET1 Q8NFU7 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.41
HIF1AN Q9NWT6 1/20 0.41
PIN1 Q13526 1/20 0.40
CNR2 P34972 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080200 0.88 GPR35 (0.42) KMORXRARXRBGPR35CNR2
SCHEMBL6080080 0.86 MCL1 (0.46) KMOALOX5RAB9AKDM4EKMT2A
SCHEMBL6079979 0.85 MCL1 (0.50) KMOALOX5RXRARXRBGPR35
SCHEMBL6080018 0.84 KMO (0.46) KMOGPR35EGLN1PIN1CNR2
SCHEMBL6080194 0.83 KMO (0.51) KMOGPR35NPC1RAB9AKDM4E
SCHEMBL17595088 0.80 KMO (0.58) KMOALOX5RXRARXRBEGLN1
SCHEMBL6080980 0.79 L3MBTL1 (0.53) KMOGPR35NPC1RAB9AL3MBTL1
SCHEMBL6080533 0.79 IGFBP3 (0.43) GPR35EGLN1EGLN3KDM4EKMT2A
SCHEMBL6080570 0.77 SCN9A (0.43) EGLN1KDM4ECSNK2A2CSNK2BCSNK2A1
SCHEMBL6080738 0.74 MCL1 (0.43) KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL KMO 91/4885ALOX5 1447/4885RXRA 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.